Xenetic Biosciences

XBIO · NASDAQ

$2.00+$0.07 (+3.63%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.93

XBIO analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated May 15, 2025

Bull case

Xenetic Biosciences Inc. has reinforced its positive outlook through the extension of its research and development partnership with The Scripps Research Institute, underscoring its commitment to advancing innovative immuno-oncology technologies. Recent preclinical studies indicate that the company's DNase technology significantly reduces tumor burden and enhances survival rates in murine models, suggesting strong therapeutic potential as an adjunctive treatment for difficult-to-treat cancers. Furthermore, strategic collaborations, such as the agreement with PeriNess, are anticipated to accelerate the clinical development of the DNase I based oncology program, strengthening Xenetic’s pipeline as it gears up for clinical trials in 2025.

Bear case

Xenetic Biosciences faces significant risks that could adversely affect its valuation, primarily including the potential for failed or inconclusive clinical trials that could halt the advancement of its innovative therapies. The company's reliance on external funding to support its development programs raises concerns about its ability to secure sufficient capital, which is critical for long-term sustainability and growth. Additionally, commercialization risks associated with bringing its therapies to market could further complicate financial stability and undermine investor confidence.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.